Hikma Pharmaceuticals has launched its 100th injectable medicine in the US.
The company’s most recent offering is Vancomycin Hydrochloride, an antibiotic for the treatment of severe infections by susceptible strains of methicillin-resistant (β-lactam- resistant) staphylococci. It can also be used for staphylococcal endocarditis.
Available in 750mg, 5g and 10g doses, the drug fights infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. It is intended for hospitalised patients that did not have an adequate response to other antibiotics, including penicillins and cephalosporins.
The medication can be adjusted, based on susceptibility data.
The use of Injectable Vancomycin Hydrochloride is restricted to infections that are caused by susceptible bacteria to minimise the development of drug-resistant bacteria and sustain effectiveness.
Hikma Pharmaceuticals injectables commercial and development executive vice-president Dan Motto said: “Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it’s another important addition to our growing US portfolio.
“This launch marks a great milestone, Hikma’s 100th injectable medicine in the US, and it demonstrates our commitment to providing doctors and hospitals with a broad range of high-quality medicines needed to treat the current and future needs of patients.”
The company noted that the parenteral Vancomycin Hydrochloride formulation may be given orally to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and for staphylococcal enterocolitis.
Data from IQVIA shows that Hikma Pharmaceuticals’ injectable Vancomycin Hydrochloride generated around $247m in US sales in the 12 months ending February 2019.